BEAM
Beam Therapeutics
$23.79
−$0.26 (−1.08%)Oct 26, 2026
Key metrics
The numbers that frame BEAM today
- Market cap
- $2.46B
- Gross margin
- 100%
- EV / Sales
- 15.9
- ROIC
- -6.9%
- Div yield
- 0%
- Debt / equity
- 0.2
- 52wk Low
- $20.23
- 52wk High
- $38.26
Growth
Revenue and earnings trend for BEAM
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about BEAM
Is Beam Therapeutics a good buy?
No. Beam Therapeutics has weak quality and weak momentum. Both signals point to a weaker setup. Growth looks poor. That could put pressure on the long-term business case. We think Beam Therapeutics is selling at a very high price.
What is the market capitalization of BEAM?
Beam Therapeutics's market capitalization is $2.46B.
What is the 52-week high for BEAM stock?
The 52-week high for Beam Therapeutics is $38.26. The current close of $23.79 is 37.8% below that high.
What is the 52-week low for BEAM stock?
The 52-week low for Beam Therapeutics is $20.23. The current close of $23.79 is 17.6% above that low.
Does BEAM stock pay dividends?
Beam Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for BEAM?
Beam Therapeutics's Debt / Equity ratio is 0.23.